tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kaveri Pohlman, 16 are a BUY (88.89%), 2 are a HOLD (11.11%).
Analyst Kaveri Pohlman, currently employed at BTIG, carries an average stock price target met ratio of 30% that have a potential upside of 39.22% achieved within 120 days.
Kaveri Pohlman’s has documented 33 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MGNX, MacroGenics at 01-Aug-2024.
Analyst best performing recommendations are on CMPI (CHECKMATE PHARMACEUTICALS).
The best stock recommendation documented was for CMPI (CHECKMATE PHARMACEUTICALS) at 3/30/2022. The price target of $9 was fulfilled within 20 days with a profit of $5.78 (179.5%) receiving and performance score of 89.75.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$3.5
$2.37 (209.73%)
$1.75
9 months 12 days ago
(28-May-2024)
2/6 (33.33%)
$1.71 (95.53%)
59
Hold
$8
$6.87 (607.96%)
$3
10 months 3 days ago
(09-May-2024)
4/9 (44.44%)
$5.96 (292.16%)
133
Hold
$3.59
$2.46 (217.70%)
$3.25
10 months 3 days ago
(09-May-2024)
7/11 (63.64%)
$1.55 (75.98%)
287
Hold
$8
$6.87 (607.96%)
$2
10 months 6 days ago
(06-May-2024)
1/3 (33.33%)
$3.63 (83.07%)
183
Sell
10 months 18 days ago
(22-Apr-2024)
0/2 (0%)
$7.4 (160.87%)
What Year was the first public recommendation made by Kaveri Pohlman?
